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 A physician ’ s perseverance 
uncovers problems in a key 
nephrology study 
 Steven  Fishbane 1 and  Jay B.  Wish 2  
 The Normal Hematocrit Cardiac Trial, published in 1998, was a 
foundational study testing erythropoietin analog treatment to normal 
hematocrit targets. It served as a warning that erythropoietin 
replacement was not a panacea. Its large size gave it disproportionate 
weighting in evidence reviews and guideline development and thereby 
impacted treatment decisions. Coyne shows that the published results 
did not completely and clearly represent the study ’ s actual results. We 
discuss the implications and make recommendations to prevent such 
occurrences. 
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 In this issue of  Kidney International , 
 Daniel W. Coyne 1 reports on critical dis-
crepancies between the 1998 publication 
of the Amgen-sponsored Normal Hema-
tocrit Cardiac Trial (NHCT) 2 and the 
actual study data as presented to the US 
Food and Drug Administration (FDA) in 
the 1996 Clinical Trial Report. It took 
more than two years and repeated prod-
ding for the study data to become avail-
able. The implications are remarkably 
important for the nephrology commu-
nity — practice guidelines based on erro-
neous data, the real possibility that 
patients may have been harmed as a 
result, and a need to understand why one 
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of the field ’ s foundational studies was 
reported with such a fundamental lack of 
clarity and completeness. 
 Th e NHCT was well intended from its 
inception, testing an implied hypothesis 
that normalization of hematocrit (Hct) 
with epoetin treatment would improve 
outcomes. The rationale was sound; 
greater oxygen carriage to organs and tis-
sues in patients with cardiovascular dis-
ease had a plausible likelihood of being 
beneficial. In total, 1233 hemodialysis 
patients with evidence of cardiac disease 
were randomized to receive epoetin alfa 
treatment to one of two Hct targets, 
30 ± 3 % or 42 ± 3 % . Th e median follow-up 
was 14 months, and the longest duration 
of treatment was 30 months. 
 Coyne 1 exposed a number of inconsist-
encies in the 1998 NHCT publication. Th e 
primary end point reporting (death or 
nonfatal myocardial infarction) was from 
the last interim analysis, adjusted for Data 
Safety Monitoring Board repeated meas-
ures, and gave the impression of statisti-
cally insignifi cant diff erences between the 
groups. Coyne found that this was not 
clearly reported; there actually was a sta-
tistically signifi cant increase in risk in the 
high-Hct group,  P  =  0.0119. Th e 95 % con-
fi dence intervals given in the abstract and 
body of the 1998  New England Journal of 
Medicine paper 2 were actually the 99.912 % 
confi dence intervals adjusted for repeated 
measures by the Data Safety Monitoring 
Board. Th e original article failed to apply 
statistical testing to the critically impor-
tant outcome of all-cause deaths; Coyne 
found there to be a statistically signifi cant 
increase in deaths in the high-Hct group, 
relative risk 1.26, 95 % confi dence interval 
1.02 – 1.56, at the last interim analysis, con-
sistent with the final trial data of 1.27 
(1.04 – 1.54) as now reported by the FDA. 
Additionally, the NHCT article failed to 
report on an important safety risk from 
the clinical trial report, other thrombotic 
events; Coyne found these to be increased 
in the high-Hct group (22.4 vs. 17.6 % , 
 P  =  0.041). 1,2 
 Th ere is a widespread misconception 
that the study found a signifi cant improve-
ment in quality of life with the higher Hct 
target; this is not correct. Th e protocol 
specifi ed quality of life as a secondary out-
come, which would typically mean a com-
parison of quality-of-life outcomes 
between the two treatment groups. Th is 
did not occur; instead the 1998 publica-
tion reported on quality of life only in 
relation to achieved Hct level without 
respect to study group allocation ( ‘ Th e 
physical-function score on the quality-of-
life questionnaire at 12 months increased 
by 0.6 point for each percentage-point 
increase in the hematocrit ( P  =  0.03). For 
example, an increase in the hematocrit 
from 30 percent to 42 percent was associ-
ated with a clinically meaningful increase 
of 7.2 points in the score on the physical-
function scale ’ 2 ). Th is reporting was prob-
lematic for the following reasons: 
 (1)  As a specifi ed secondary end point, 
the credible outcome to report is the 
result of the outcome in each group, 
together with the diff erence bet-
ween the groups, the eff ect size. 3 
 (2)  A secondary,  post hoc analysis by 
achieved Hct level would have been 
acceptable, but only aft er reporting 
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of the diff erence in the outcome bet-
ween the study groups. 
 (3)  Th e choice of language in the second 
sentence was unfortunate and may 
appear as an intent to mislead. Th e 
two Hct levels of 30 and 42 % selected 
by the authors for the  example are the 
exact Hct levels of the two interven-
tion-group Hct targets. As a result, 
many readers may have come away 
with the  impression that the 42 % 
Hct target group had better physical 
functioning than the 30 % Hct target 
group, which was not the case. 
 (4)  As Coyne has now exposed, there 
were actually no diff erences in 
any of the quality-of-life measures 
 between the treatment groups. 2 
 At the time of the 2001 and 2006 / 2007 
Kidney Disease Outcomes Quality Ini-
tiative (KDOQI) anemia guidelines, 
the NHCT had the greatest evidentiary 
value of any published study on hemo-
globin (Hgb) targets because of its large 
sample size, 1233 patients (the next larg-
est study had 596; most other studies had 
fewer than 200 patients). 4,5 Accordingly, 
the results of this study had a dispropor-
tionate impact on evaluation of evidence 
from the literature. Th is may at least 
partially explain why the anemia guide-
lines published in 2006 recommended 
an increase in the target Hgb range to 
11 – 13  g / dl. 4 Following publication of 
the Correction of Hemoglobin and Out-
comes in Renal Insuffi  ciency (CHOIR) 
trial and the Cardiovascular Risk Reduc-
tion by Early Anemia Treatment with 
Epoetin Beta (CREATE) trial, 6,7 both 
of which helped to more fully elucidate 
the risk profi le of epoetin treatment to 
near-normal Hgb targets, a 2007 update 
to the KDOQI guidelines recommend-
ed reverting to a general Hgb target of 
11 – 12  g / dl. 5 But this was still with the 
mis understanding as to results for qual-
ity of life in the NHCT (Table 3 in the 
guideline shows positive physical-func-
tioning results from this study). 
 Taken together, the lack of clear and 
complete reporting of safety and quality-
of-life fi ndings from the NHCT repre-
sents a deviation from scientifi c reporting 
standards. Th is needs to be prevented in 
the future by adherence to procedures 
that would promote accurate and credible 
reporting of study results ( Figure 1 ). 
First, authors should be given access to 
and should review the full clinical trial 
data. As stated by Davidoff   et al. for the 
editors of several journals,  ‘ the sponsor 
must impose no impediment, direct or 
indirect, on the publication of the study ’ s 
full results. ’ 8 This requires unfettered 
access for authors.  JAMA requires that at 
least one author  ‘ had full access to all of 
the data in the study and takes responsi-
bility for the integrity of the data and the 
accuracy of the data analysis. ’ Second, for 
statistical analysis,  JAMA requires that 
 ‘ an additional independent analysis of the 
data must be conducted by statisticians 
at an academic institution. ’ 9 Th is might 
be excessive, given the resources of the 
pharmaceutical sponsor; we would sug-
gest that it would seem reasonable for the 
sponsor to provide statistical support to 
the authors. Th e authors, however, bear 
the responsibility for data  interpretation 
and should perform additional analyses 
as required. Th ird, although it is accept-
able for employees of the sponsor to par-
ticipate in the authorship process, the 
primary decision-making and writing 
responsibilities should lie with the exter-
nal authors. Fourth, the roles of all 
authors should be clearly explained in all 
published studies. Finally, there should 
be adherence to the Consolidated Stand-
ards of Reporting Trials (CONSORT) 
Statement, a published set of recommen-
dations that improve the reporting of 
 trials by  ‘ facilitating their complete and 
transparent reporting, and aiding their 
critical appraisal and interpretation. ’ 10 
 Finally, how do the newly understood 
results of the NHCT aff ect our knowledge 
of the benefi t-and-risk balance of treat-
ment with erythropoietin-stimulating 
agents (ESAs), and what is the impact on 
treatment recommendations? Th e NHCT 
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results
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 Figure 1  |  Recommendations to promote integrity in publication of pharmaceutical-sponsored studies. 
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taken together with other key randomized 
controlled trials on Hgb target yields the 
following conclusions: 
 (1)  Th ere is a clear and consistent sig-
nal of increased risk with ESA treat-
ment to near-normal Hgb targets. 
 (2)  All such risk has occurred with 
 the intent to target Hgb levels of 
13  g / dl or higher. 
 (3)  Th e risk has been demonstrated with 
use of ESAs to target these near-
normal Hgb levels for  prolonged 
periods of time . 
 (4)  Post hoc analyses have not found 
that achieved Hgb concentration is 
associated with risk. Th ese obser-
vations can be hypothesis-generat-
ing only; the foundational fi nding 
is that intent to target Hgb levels of 
13  g / dl or higher results in adverse 
outcomes. 
 (5)  Th e safety of lower Hgb targets dur-
ing ESA treatment has not been 
studied. 
 (6)  Th e mechanism of harm is unknown. 
 We would suggest that there is clear bene-
fi t, and probably limited risk, to treatment 
with ESAs for severe anemia, up to Hgb 
targets of 10 – 11  g / dl. Th ere is currently 
great uncertainty as to the balance of 
benefi t and risk with prolonged treatment 
to Hgb targets between 11 and 13  g / dl. In 
most cases, ESA treatment should not 
be targeted to this Hgb range, because 
of the possibility of increased risk. But, 
in special cases in which  physician and 
patient can substantively discuss risks and 
benefi ts, then informed shared decision 
making may make ESA treatment in this 
Hgb range acceptable for symptom relief. 
It should be noted, however, that the cur-
rent FDA prescribing instructions recom-
mend reducing or interrupting ESA dose 
when Hgb rises to 10 – 11  g / dl. 11 
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